Atrion (NASDAQ: ATRI) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Institutional & Insider Ownership
59.2% of Atrion shares are owned by institutional investors. Comparatively, 37.1% of Ocular Therapeutix shares are owned by institutional investors. 23.1% of Atrion shares are owned by company insiders. Comparatively, 26.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and recommmendations for Atrion and Ocular Therapeutix, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ocular Therapeutix has a consensus price target of $20.67, indicating a potential upside of 320.91%. Given Ocular Therapeutix’s higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Atrion.
Valuation & Earnings
This table compares Atrion and Ocular Therapeutix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atrion||$143.49 million||7.05||$27.58 million||$18.05||30.30|
|Ocular Therapeutix||$1.89 million||96.46||-$44.70 million||($2.27)||-2.16|
Atrion has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
This table compares Atrion and Ocular Therapeutix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.9%. Ocular Therapeutix does not pay a dividend. Atrion pays out 26.6% of its earnings in the form of a dividend. Atrion has raised its dividend for 15 consecutive years.
Volatility & Risk
Atrion has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Atrion beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.